References
- EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.
- Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis.B. Lancet 2003;362:2089–94.
- Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444–8.
- Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat 2007;14:835–40.
- Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carriho FJ, Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422–30.
- Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503–14.
- Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B Korean. J Hepatol 2009;15:S13–24.
- Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890–7.
- Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Multimer D, Deterding K, Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443–51.
- Lampertico P. Partial virological response to nucleos(t)ide analogues in naive patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009;50:644–7.
- Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004;40:837–44.
- Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WEt. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625–33.
- Hadziyannis SJ. Milestones and perspectives in viral hepatitis B Liver. Int 2011;31:129–34.
- Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48:S2–19.
- Lai CL, Gane E, Liaw YF, Hsu CW, Tongsawat S, Wang Y, Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576–88.
- Lee M, Keeffe EB. Study of adherence comes to the treatment of chronic hepatitis B. J Hepatol 2011;54:6–8.
- Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011;54:12–18.
- Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498–507.